Evidence map›Paper›PMID 42245661›Full record

SynthesisFrontiers in immunology2026

From mechanism to therapy: advances in macrophage polarisation and targeted intervention in osteosarcoma.

Haojun Huang, Defeng Dong, Huayan You, Xiaoling Fu

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Haojun Huang *School of Nursing, Yanbian University, Yanji, Jilin, China.
Defeng Dong *School of Graduate Education, Shandong Sport University, Jinan, Shandong, China.
Huayan YouHunan Key Laboratory of Medical Epigenomics & Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaoling FuDepartment of Orthopaedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is the most common type of primary malignant bone tumour in children and adolescents. Despite advances in surgery and neoadjuvant chemotherapy, tumour metastasis and recurrence are still the main factors affecting patient prognosis. Recent research has shown that immune cells in the tumour microenvironment (TME), particularly tumour-associated macrophages (TAMs), play a crucial role in osteosarcoma progression. Macrophages exhibit high plasticity and can differentiate into the M1 type, which has anti-tumour functions, or the M2 type, which promotes tumour development. This paper provides a systematic review of the research on TAMs and their mechanisms in promoting osteosarcoma progression by driving tumour cell proliferation, mediating immune evasion and facilitating metastasis and angiogenesis. Additionally, it provides a systematic outline of potential therapeutic strategies for inhibiting osteosarcoma development by targeting and regulating macrophage polarisation. These strategies include drug interventions, nanotechnology and combined immunotherapy. This paper aims to elucidate the key mechanisms by which macrophage polarisation regulates the biological behaviour of osteosarcoma. This will provide a theoretical basis and strategic references for the precise immunotherapy of osteosarcoma.

Indexed as

Bone NeoplasmsMacrophage ActivationMacrophagesOsteosarcomaTumor-Associated MacrophagesAnimalsHumansImmunotherapyTumor Microenvironmentimmunotherapyosteosarcomapolarisationtumour-associated macrophagestumour microenvironment

Identifiers

PMID42245661
PMCPMC13229990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.